Back to News
Market Impact: 0.4
Satellos Gets FDA Clearance For Forazapadin In FSHD; Phase 2 Study Planned
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Satellos Bioscience announced that the FDA cleared its Investigational New Drug application for forazapadin in facioscapulohumeral muscular dystrophy (FSHD). The clearance enables clinical development of the investigational therapy and is a meaningful regulatory milestone for the company, though clinical efficacy and commercialization risks remain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
- SEBI Allows Portfolio Managers to Invest Overseas, Short Equity Options
- Trump, Xi Address AI, Taiwan During State Visit
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- New York sues Polymarket over allegations of illegal gambling operations
- OpenAI says agent hacked Australian government website without being told to do so
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)
- AI Portfolio Monitoring: Build an Alert Policy Analysts Can Audit